Chloe Kent
Reporter
Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.
Latest From Chloe Kent
Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy
Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.
Shared Savings Legislation Could Increase Medicare Biosimilar Access
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.
Canadian Generics Group Launches Cost-Saving Campaign
The CGPA is drawing attention to the cost savings Canadians can benefit from through the use of generic drugs via a PSA-style digital campaign.
Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business
Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.
California Snaps Up Civica For Biosimilar Insulin Initiative
Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.
Shared Savings Legislation Could Increase Medicare Biosimilar Access
Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.